Inogen’s Post

C-Life CBM-IUI Mini-Macro Cell-Bank-Medculture Bone-Cartilage-Scaffold Bone-Marrow-Blood-Lymph Immune-Stromal-Stem-Red-Cell Antibody-Antigens-Human-mRNAs Individual-Universal-Immunotherapy Oxygenation-Filtration-Nutrition-Circulation https://lnkd.in/e2S8NFEK

Vicore Pharma AB is pleased to announce positive final results from the Phase 2a AIR trial demonstrating that buloxibutid improves lung function over 36 weeks in patients with idiopathic pulmonary fibrosis (#IPF). These encouraging results were presented yesterday by Toby Maher, Keck School of Medicine of USC, as a late-breaking oral session at the American Thoracic Society International Congress (#ATS2024). Vicore will be discussing the results in more detail during a webinar on Wednesday 5/22 at 10:00 ET/16:00 CET. You can register for the webinar here: https://lnkd.in/eKp8xYGj #pulmonaryfibrosis #biotechnews #respiratory #clinicaldata

𝐀𝐫𝐞 𝐲𝐨𝐮 𝐥𝐨𝐨𝐤𝐢𝐧𝐠 𝐟𝐨𝐫 𝐞𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐰𝐚𝐲𝐬 𝐭𝐨 𝐦𝐚𝐧𝐚𝐠𝐞 𝐩𝐚𝐢𝐧 𝐚𝐧𝐝 𝐢𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐢𝐨𝐧 𝐟𝐫𝐨𝐦 𝐬𝐩𝐨𝐫𝐭𝐬 𝐢𝐧𝐣𝐮𝐫𝐢𝐞𝐬? Join our exclusive webinar, "𝐒𝐩𝐨𝐫𝐭𝐬 𝐈𝐧𝐣𝐮𝐫𝐢𝐞𝐬, 𝐏𝐚𝐢𝐧 & 𝐈𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐢𝐨𝐧: 𝐇𝐨𝐰 𝐃𝐨 𝐘𝐨𝐮 𝐓𝐫𝐞𝐚𝐭 𝐓𝐡𝐞𝐦?" led by renowned experts Dr. Med Alberto Schek and Peter Stiller, 𝐢𝐧 𝐆𝐞𝐫𝐦𝐚𝐧 𝐥𝐚𝐧𝐠𝐮𝐚𝐠𝐞. Discover innovative, patient-centered, and top-class conservative approaches used in competitive sports, including: • Enzyme Therapy • Autologous Blood Therapy • Electrolyte Therapy • Shockwave Therapy • Phytopharmaceuticals • Laser Therapy • Magnetic Resonance Therapy • Cryotherapy Plus: • Gain valuable insights from real-world case studies and participate in a live Q&A session with the speakers! Don't miss this opportunity to: • Learn more about regenerative sports medicine • Explore effective strategies for managing pain and inflammation • Gain insights from practical case studies • Ask your questions directly to the experts during the live Q&A Register NOW for FREE and secure your spot! Click here to register: bit.ly/wobenzym-webinar “𝐏𝐥𝐞𝐚𝐬𝐞 𝐧𝐨𝐭𝐞 𝐭𝐡𝐚𝐭 𝐧𝐨𝐭 𝐚𝐥𝐥 𝐜𝐨𝐧𝐭𝐞𝐧𝐭 𝐦𝐚𝐲 𝐚𝐩𝐩𝐥𝐲 𝐢𝐧 𝐲𝐨𝐮𝐫 𝐜𝐨𝐮𝐧𝐭𝐫𝐲, 𝐚𝐬 𝐧𝐨𝐭 𝐚𝐥𝐥 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐬 𝐨𝐟 𝐭𝐡𝐞 𝐛𝐫𝐚𝐧𝐝 𝐖𝐨𝐛𝐞𝐧𝐳𝐲𝐦 𝐚𝐫𝐞 𝐫𝐞𝐠𝐢𝐬𝐭𝐞𝐫𝐞𝐝 𝐚𝐬 𝐚 𝐝𝐫𝐮𝐠.” #𝐬𝐩𝐨𝐫𝐭𝐬𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 #𝐬𝐩𝐨𝐫𝐭𝐬𝐢𝐧𝐣𝐮𝐫𝐲 #𝐩𝐚𝐢𝐧𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 #𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞𝐩𝐫𝐨𝐟𝐞𝐬𝐬𝐢𝐨𝐧𝐚𝐥𝐬

👋 Today we present to you: Guidewire Retention by the Venous Cannula of Veno-Arterial Extracorporeal Membrane Oxygenation by Sebastian Bratke and Jan A. Graw https://lnkd.in/g_uJkG5S

This narrative review explores the advancements in managing distal limb perfusion in venoarterial extracorporeal membrane oxygenation (VA ECMO) with femoral artery cannulation. Initially, no specialized techniques like distal perfusion cannulae were used, leading to limb ischemia. #DistalLimbPerfusion #FemoralArteryCannulation #LimbIschemiaManagement #VenoarterialECMO

🌬️ Advancing Oxygen Therapy: A New FiO2 Prediction Formula 🌬️ 🔍 In the quest to enhance low-flow oxygen therapy, a pivotal study introduces the a revised Duprez formula, the New FiO2 Prediction Formula (NFiO2). This innovative approach aims to accurately determine the inspired oxygen fraction (FiO2), a crucial element often unknown in such therapies. Methodology: Utilized a T-piece connected to an artificial lung, varying ventilatory parameters like tidal volume, respiratory rate (RR), and O2 flow rates. The study adapted the 2018 Duprez Formula for practical application, focusing on RR and O2 flow rate. Findings: NFiO2 and the Duprez Formula 2018 emerged as the most precise, surpassing others like the Vincent and Shapiro Formulas. https://lnkd.in/eccAieaa #HealthcareInnovation #OxygenTherapy #MedicalResearch #PatientCare #FiO2Precision

Our webinar on "Advanced Endovascular Management of Pulmonary Embolism: What Does Real World Data Show Us?" is now available on demand. Dive into the latest insights and strategies in pulmonary embolism therapy options at your convenience: https://lnkd.in/dEeVmvfp Supported by Boston Scientific

Ananda Developments Plc (AQSE:ANA) finance director Jeremy Sturgess-Smith shares promising results from preclinical studies investigating the efficacy of MRX1 in treating cardiac fibrosis and heart failure with preserved ejection fraction (HFpEF). Sturgess-Smith explained that Ananda Developments acquired MRX Medical, the company that owns the MRX1 IP, last year. The company specialises in chronic inflammatory pain conditions and cannabis-based medicinal treatments. The study shows that dosing MRX1 in mice with heart failure and preserved ejection fraction can bring heart and lung weight back to healthy levels and significantly reduce heart failure compounds. Sturgess-Smith emphasised the high unmet medical need in treating heart failure, with limited options beyond diet and exercise. Ananda Developments aims to include MRX1 as part of its treatment portfolio, alongside its existing two Phase II trials investigating... Watch at #Proactive #ProactiveInvestors http://ow.ly/JkEF105ye5S

We invite you to explore the science behind red blood cell (RBC) storage. As soon as blood is collected, #RBCs begin to degrade as a result of oxidative damage. Such degradation combined with storage in an oxygen permeable bag reduces the quality, viability, and functionality of RBCs, thereby affecting their ability to deliver oxygen in a patient following #transfusion. Learn more: https://lnkd.in/d69r_9NW #Hemanext #HemanextONE #StoredRBCs